We set the threshold of at least 5% of lymphoma cells with PD-L1 expression for PD-L1 positivity in tumor cells and at least 20% of malignant and non-malignant cells with PD-L1 expression for PD-L1 positivity in tumor microenvironment, conforming to the cut-point used in a previous publication [14]. Here, CD274 is linked to neoplasm.